Financing Technology's Frontier: Decision-Making Models for Investors and Advisors
An indispensable resource for anyone interested in the future of emerging technology industries
Financing Technology's Frontier draws upon the experiences of today's most successful venture capitalists and entrepreneurs to provide investment professionals expert insight and powerful tools for identifying and capitalizing on the most promising high-tech and biotech opportunities. It also includes proven business models and many fascinating and instructive case studies that help entrepreneurs, CEOs and CFOs learn from the successes and setbacks of other companies in their sectors.
Richard Shanley (New York, NY) is a partner in the Health Services and New Media division at Deloitte Touche Tohmatsu.
What people are saying - Write a review
We haven't found any reviews in the usual places.
CHAPTER 1 Sharing the Excitement of Discovery
CHAPTER 2 Growth Models that Encourage Investment
CHAPTER 3 Where to Find CapitalPart I Venture Capital
CHAPTER 4 Where to Find CapitalPart II Public Markets and Private Placements
CHAPTER 5 Creative and Alternative Financing Strategies
CHAPTER 6 Strategic Alliances and Corporate Partnerships
CHAPTER 7 Mergers and Acquisitions
CHAPTER 8 Profiles of Corporate Partnerships
CHAPTER 9 Tax Planning Strategies
CHAPTER 10 How to Attract and Retain Quality Employees and Management Teams
CHAPTER 11 Corporate Governance in a PostEnron World
CHAPTER 12 Biotechnology Beyond the US Borders
CHAPTER 13 Technologys FutureThe View from the Frontier
Other editions - View all
Financing Technology's Frontier: Decision-Making Models for Investors and ...
Richard P. Shanley
No preview available - 2004
accredited investors activities Advanced NMR agreement amount angel angel investors Apax Partners asset-based asset-based lending bear market biotech companies biotech industry biotechnology cash collaboration commercial company’s corporate partner corporate partnerships create deal Deloitte 86 discovery drug early-stage emerging company employee entity entrepreneurs equity equity-based compensation financing future gene Genencor Genencor International genetic grant growth healthcare high-tech and biotech Human Genome Human Genome Sciences income initial public offering innovation institutional internal control Internet investment investors lender liability licensing loan management team ment Merck KGaA milestone payments million Nasdaq pany percent pharmaceutical potential private placement public offering raise relationship restricted stock revenues RScD Sarbanes-Oxley SBIR securities share shareholders Small Business SmithKline stock options strategy successful tech technology company therapeutic tion venture capital venture capital firms venture capitalists